Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma

Published:2016-05-11 Issue:3 Volume:58 Page:e109-e112
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Australas J Dermatol

Author:

Parakh Sagun¹²³,Nguyen Rebecca⁴,Opie Jacinta M⁴,Andrews Miles C¹²³

Affiliation:

1. Medical Oncology Unit; Austin Health; Melbourne Vic. Australia

2. Olivia Newton-John Cancer Research Institute; Melbourne Vic. Australia

3. La Trobe University School of Cancer Medicine; Melbourne Vic. Australia

4. Dermatology Unit; Austin Health; Melbourne Victoria Australia

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajd.12488/fullpdf

Reference13 articles.

1. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL);Ribas;J. Clin. Oncol.,2014

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N. Engl. J. Med.,2015

3. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N. Engl. J. Med.,2015

4. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 3 trial;Ribas;Lancet Oncol,2015

5. Management of immune-related adverse events and kinetics of response with ipilimumab;Weber;J. Clin. Oncol.,2012

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid;Frontiers in Oncology;2023-03-03

2. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors;Cancers;2022-11-05

3. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer;JAMA Dermatology;2022-08-01

4. Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study;Frontiers in Immunology;2022-07-22

5. Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients—Focus on Clinical and Histopathological Variation;Dermatopathology;2022-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3